Canada: Follow-On Biologics In Canada

Originally published in Update 2008, Issue 3. With permission from FDLI,

Health Canada has released a draft guidance document entitled "Information and Submission Requirements for Subsequent Entry Biologics (SEBs)." This document outlines the regulatory review process that Health Canada will use for a biologic that is similar to an approved innovator biologic.1

Biologics are drug products derived from biological sources that are listed on Schedule D of Canada's Food and Drugs Act. The list includes blood products, cells and tissues, gene therapies, vaccines, radiopharmaceuticals and therapeutic products derived through biotechnology. Schedule D products may be listed as individual products (insulin), as product classes (immunizing agents), by reference to a particular source of the product (drugs, other than antibiotics, prepared from microorganisms) or by the methodology used to produce the biologic (drugs obtained by recombinant DNA procedures). Research and development costs for biologics are generally considerably greater than for conventional pharmaceutical drugs because biologics are structurally complex and difficult to manufacture. Small changes in manufacturing protocols for biologics can lead to considerable differences in terms of the quality, safety and efficacy of an end product.

An SEB is defined by Health Canada as "a biologic product that would enter the market subsequent to, and similar to, an approved innovator biologic, which would rely in part, on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to a reference biologic product." SEBs are sometimes called "generic" or "follow-on" biologics or "biosimilar" products. Health Canada does not endorse the use of the term "generic" biologic because this description incorrectly implies that the same approval process and marketed use for conventional generic drugs will apply to SEBs. Furthermore, because of their complex molecular structure and the unique manufacturing processes used to develop biologics, it is practically impossible for an SEB to be identical to a previously approved biologic, as a generic would be to its brand name drug. The term "follow-on" biologic is used by the U.S. Food and Drug Administration to describe biologics with similar medicinal ingredients, and the regulatory framework for these products is currently under debate.

A reference biologic is one that has received marketing approval from Health Canada on the basis of a complete quality, safety and efficacy assessment, including clinical trial data. The pharmaceutical form, strength and route of administration of the SEB is the same as that for the reference product. A manufacturer can demonstrate that a new biologic is "similar" to an approved reference product through comparative studies, relying upon data that have previously been generated for an innovator manufacturer. If the manufacturer so demonstrates, the approval process for an SEB may be considerably streamlined compared with that of an innovative biologic.

Once a Notice of Compliance is granted for an SEB, it is regulated like any other biologic as regards post-marketing surveillance. Because biologics have the potential to cause immunogenic reactions in the body, pharmacovigilence and adverse event reporting are particularly important to ensure patient safety.

Regulatory Framework for Biologics and SEBs

Like conventional pharmaceutical drugs, biologics are approved for sale in Canada through the new drug submission (NDS) process outlined in Division 8 of the Food and Drug Regulations. Health Canada's draft guidance document on SEBs indicates that the existing frameworks for biologic, pharmaceutical and generic drugs will provide the regulatory framework for SEBs and, if appropriate, the practices for regulating generic drugs will be applied to SEBs.

To be approved through the SEB pathway, a product must demonstrate "similarity" to an appropriate reference product, which will normally be a product approved in Canada, through an extensive comparison between the products. An appropriate reference product is one that has been on the market for a sufficient period of time to generate a substantial amount of safety and efficacy data. An SEB should not be used as a reference product. The determination of similarity is based upon analytical testing, biological assays, clinical data and non-clinical data as outlined in detail in the draft guidance document. The extent of clinical data required to support an NDS will depend on the level of similarity demonstrated between the SEB and its reference product. Even if they contain similar active ingredients, a product utilizing a different manufacturing process from that of its reference biologic will not be eligible for the SEB regulatory pathway. A full set of chemistry and manufacturing data will also be required as part of the SEB submission package.

One significant difference between the regulation of generic pharmaceuticals and that of SEBs pertains to the use of an innovator's product monograph. Unlike the case for generic drugs, the manufacturer of an SEB cannot use the product monograph of the reference biologic, so instead is required to develop its own monograph in accordance with Health Canada policies.

A Notice of Compliance on an SEB will not automatically be granted for all the indications of its reference product. The indications for a particular SEB will be based on the data submitted during the NDS process and will be subject to considerations such as the level of reliance on the reference product, the demonstrated level of similarity, and the availability of postmarket information.

Patent Register and Data Exclusivity

The guidance document indicates that biologics, like traditional pharmaceutical drugs, are subject to the same provisions of the Patented Medicines (Notice of Compliance) Regulations (PM (NOC) Regulations) and the Food and Drug Regulations (Data Protection). Specifically, biologics that meet the definition of an "innovative drug" under C.08.004.1 of the Food and Drug Regulations may be eligible for an eight-year term of data protection (with an extra six-month period for pediatric indications). During this time, any data submitted to Health Canada relating to the innovative drug may not be used by competitors seeking marketing approval of an SEB. Patents that claim the medicinal ingredient, formulation or dosage form of a biologic, or an indication for the biologic, for which drug regulatory approval is sought may be listed on the Patent Register and therefore subject to the protections of the PM (NOC) Regulations.

Stakeholders have expressed concern over the applicability of the PM (NOC) Regulations and the data protection provisions of the Food and Drug Regulations within the current framework for biologic approval. In particular, the exclusions from the Patent Register of purely process patents and/or patents on processing intermediates may result in inadequate protection for innovator biologics because, unlike conventional pharmaceuticals, manufacturing protocol is absolutely critical to biologic production. The listing of a patent claiming the "medicinal ingredient" of a biologic, or a dosage, formulation or use thereof, may not sufficiently protect an innovator's intellectual property rights. An SEB manufacturer could circumvent the PM (NOC) Regulations in claiming that its SEB is not identical to that of listed biologic, while still referencing the biologic for the purposes of demonstrating similarity for regulatory approval. Parallel concerns have been raised with respect to the definition of an "innovative drug" for the purposes of data protection under the Food and Drug Regulations. The term "variation" in this context must be properly interpreted so that truly innovative biologics utilizing a unique manufacturing process are afforded data protection, whereas biologics that seek approval on the basis of a direct or indirect comparison to a previously approved product do not. Amendments to both the PM (NOC) Regulations and the data protection provisions in the Food and Drug Regulations may be necessary to foster innovation in this field.

Proposed Amendments To the Regulations

The guidance document indicates that the Food and Drug Regulations will be amended to provide a comprehensive legal basis for the regulatory framework of SEBs. The amendments will include changes to the NDS pathway that are specific to SEBs with demonstrated similarity to a reference biologic. Additional guidance documents on biologics will be released that will detail information and data requirements for specific classes of SEB products. Health Canada intends to harmonize the approval process for SEBs, to the extent possible, with other regulators and international organizations such as the World Health Organization and the International Conference of Harmonization.

Several Canadian patents covering biologics have either recently expired or will expire shortly. An increase is therefore expected in the number of NDS filings and issued Notices of Compliance on SEBs over the coming years. Health Canada states that the regulatory framework for SEBs is "not intended to be a disincentive for innovation nor become unduly burdensome for SEB sponsors." Further guidance from Health Canada will be necessary to ensure that the approval process for all biologics is fair and efficient. As discussed above, amendments to the PM (NOC) Regulations and the data protection provisions may also be required.

In light of the current and future interest in SEB products, innovator biologic manufactures should carefully consider their regulatory strategy to ensure that inventive products are protected to the full extent permitted under the PM (NOC) Regulations and the Food and Drug Regulations (Data Protection) as these currently read. Such a regulatory strategy would include an assessment whether a biologic is an "innovative product" and particular attention to the claim language in all patents relating to the product.


1. Available at brgtherap/activit/consultation/seb-pbu/index_ e.html.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions